⁶⁸Ga‐PSMA‐PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment

Abstract

⁶⁸ Ga-PSMA-PET imaging showed a high clinical impact on staging and RT management in patients with biochemically recurrent PC, even at low serum PSA levels. With 43% changes in staging and 59% in radiotherapy planning ⁶⁸ Ga-PSMA-PET could lead to an indispensable tool in guiding radiation treatment in recurrent PC.